Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 5/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.44 |
| ▸ | CDK14 | O94921 | 2/20 | 0.43 |
| ▸ | CCNY | Q8ND76 | 2/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.43 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481529 | 0.82 | IRAK1 (0.55) | ACKR3BTKCDK14CCNYPIP4K2A | |
| SCHEMBL21481480 | 0.82 | CDK14 (0.46) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL21481477 | 0.80 | CTSC (0.64) | EGFRBTKCTSCITK | |
| SCHEMBL21344948 | 0.78 | DHODH (0.56) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL16095303 | 0.77 | EGFR (0.54) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL12518702 | 0.77 | EGFR (0.54) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL16095361 | 0.76 | MAOB (0.58) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL16095359 | 0.76 | MAOB (0.58) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL16665163 | 0.76 | ITK (0.64) | ACKR3EGFRBTKITKJAK3 | |
| SCHEMBL31069490 | 0.75 | PARP1 (0.65) | EGFRBTKITKJAK3ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2019197546-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | ACKR3 2216/4885EGFR 2944/4885BTK 528/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | ACKR3 837/4885EGFR 4412/4885BTK 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.